Domain-informed effector gene assignment exposes training-data dependence of drug target prioritisation from GWAS
En palabras de los autores
About 90% of trait-associated lead variants lie outside protein-coding regions, so nominating the effector gene at genome-wide association study (GWAS) loci remains the principal bottleneck in translating associations into biological insight. Since no experimentally resolved ground truth exists at scale, every method rests on quasi-true-positive sets dominated by a single line of evidence. Here, we benchmarked established prioritisation methods across three independent evaluation sets, trained five models each informed by a different biological domain, and annotated lead variants for six common diseases. Performance did not transfer across domains (AUPRC 0.91 to 0.46 for the same method), and we traced this to how differently models weight the distance between variant and gene (p<5.3x10-123), not to how they were built. Curation assumptions propagated into predictions and can become self-confirming, such as druggability in the Open Targets-informed model. The five models shared only 17.1% to 31.8% of effector gene assignments, converging on established disease biology but diverging where GWAS are expected to yield novel insight. Recovery of 340 approved drug targets differed markedly between models, and no way of combining them, by averaging scores (38.8%) or training on all curations jointly (36.5%), approached the 52.1% recovered across all five together. Our workflow matched Open Targets L2G across three annotation sets without prior biological knowledge and exceeded it where curated knowledge already linked gene and disease. We provide the Domain-informed EFfector gene Assignment framework (DEFA; https://github.com/lkohleick/DEFA), which reports rather than hides the curation assumption behind each gene assignment so that it can be examined and tested.
Apareció: jueves, 19 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.